Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (748) Arixtra, Organon, Sanofi-Synthelabo,
...complications • Mild irritation at injection site • Anemia • Fever • Nausea • Edema • Constipation Mechanism of Action Arixtra (fondaparinux sodium) exhibits antithrombotic activity, which is the result of antithrombin III (ATIII)-mediated selective inhibition of Factor Xa. By selectively binding to ATIII, fondaparinux sodium activates the innate neutralization of Factor Xa by ATIII. This neutralization interupts the blood ...
View Page

2.  CenterWatch: New Medical Therapies in Disease Category (305), Abdominal Cancer
...ISMRM) in Toronto. Sanofi-Synthelabo reported positive results from a general surgery study investigating Arixtra (fondaparinux) , a selective factor X inhibitor for the treatment of venous thromboembolism (VTE). Results showed that ...
...dalteparin for the prevention of VTE following major abdominal surgery. In abdominal cancer surgery subjects, fondaparinux was significantly more effective than the low molecular weight heparin. The randomized, double blind study ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (147), Thrombosis
...ISMRM) in Toronto. Sanofi-Synthelabo reported positive results from a general surgery study investigating Arixtra (fondaparinux) , a selective factor X inhibitor for the treatment of venous thromboembolism (VTE). Results showed that ...
...dalteparin for the prevention of VTE following major abdominal surgery. In abdominal cancer surgery subjects, fondaparinux was significantly more effective than the low molecular weight heparin. The randomized, double blind study ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (355), Orthopedic Surgery
...the Penthifra Plus study involving 656 subjects undergoing surgery for hip fracture showed that Arixtra (fondaparinux) administered for four weeks significantly reduces the incidence of deep venous thrombosis (DVT), compared to ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (315), Hip Replacement
...the Penthifra Plus study involving 656 subjects undergoing surgery for hip fracture showed that Arixtra (fondaparinux) administered for four weeks significantly reduces the incidence of deep venous thrombosis (DVT), compared to ...
View Page

6.  CenterWatch: New Medical Therapies in Disease Category (302), Vascular Diseases
...ISMRM) in Toronto. Sanofi-Synthelabo reported positive results from a general surgery study investigating Arixtra (fondaparinux) , a selective factor X inhibitor for the treatment of venous thromboembolism (VTE). Results showed that ...
...dalteparin for the prevention of VTE following major abdominal surgery. In abdominal cancer surgery subjects, fondaparinux was significantly more effective than the low molecular weight heparin. The randomized, double blind study ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (85), Hypertension (High Blood Pressure)
...ISMRM) in Toronto. Sanofi-Synthelabo reported positive results from a general surgery study investigating Arixtra (fondaparinux) , a selective factor X inhibitor for the treatment of venous thromboembolism (VTE). Results showed that ...
...dalteparin for the prevention of VTE following major abdominal surgery. In abdominal cancer surgery subjects, fondaparinux was significantly more effective than the low molecular weight heparin. The randomized, double blind study ...
View Page